Unicycive Therapeutics In... (UNCY)
NASDAQ: UNCY
· Real-Time Price · USD
0.75
0.07 (10.07%)
At close: Jun 16, 2025, 3:59 PM
Company Description
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States.
It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury.
The company was incorporated in 2016 and is based in Los Altos, California.
Unicycive Therapeutics Inc.
| Country | United States |
| IPO Date | Jul 12, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Dr. Shalabh K. Gupta M.D., MPA |
Contact Details
Address: 4300 El Camino Real Los Altos, California United States | |
| Website | https://www.unicycive.com |
Stock Details
| Ticker Symbol | UNCY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001766140 |
| CUSIP Number | 90466Y103 |
| ISIN Number | US90466Y1038 |
| Employer ID | 81-3638692 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shalabh K. Gupta M.D., MPA | Founder, Chairman, Chief Executive Officer & President |
| John W. Townsend CPA | Chief Financial Officer |
| Douglas Jermasek M.B.A. | Executive Vice President of Corporate Strategy |
| Dr. Pramod Gupta Ph.D. | Executive Vice President of Pharmaceutical & Business Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 13, 2025 | 424B5 | Filing |
| Jun 10, 2025 | 8-K | Current Report |
| Jun 09, 2025 | DEFA14A | Filing |
| Jun 09, 2025 | 8-K | Current Report |
| May 22, 2025 | DEFA14A | Filing |
| May 21, 2025 | DEFA14A | Filing |
| May 21, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |